4D Path Announces Strategic Financing and Board Appointments
4D Path, a company focused on personalizing cancer care, has announced the first close of a strategic financing round aimed at developing treatment predictive biomarkers for clinical use. This financing is intended to support partnerships with Biopharma companies and enhance the company’s innovative approach to predicting tumor responses to therapy. The company also announced the appointment of Katherine Vega Stultz and Robert J. Hombach to its Board of Directors.
NEWTON, Mass.–(BUSINESS WIRE)– #4DPath–4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path’s strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatment sel